Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label study of D961H in Japanese pediatric patients with reflux esophagitis or NSAID/aspirin-associated peptic ulcer
jRCT2080223965Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esomeprazole in erosive esophagitis (EE), gastric ulcer, duodenal ulcer and 1 more (4 arms), sponsored by AstraZeneca. Started Jul 2018; status: completed.
02
Drugs
esomeprazole
03
Conditions
erosive esophagitis (EE)gastric ulcerduodenal ulcerPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT2080223965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223965.